Ironwood Pharmaceuticals Appoints Jay P. Shepard to Board of Directors
December 03 2020 - 8:30AM
Business Wire
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced
the appointment of Jay P. Shepard to its Board of Directors,
effective immediately. Mr. Shepard will also serve as a member of
the Audit Committee. Following the appointment of Mr. Shepard, the
Board is now composed of 11 directors, nine of whom are
independent.
“We are excited to welcome Jay to Ironwood’s Board. Jay is a
recognized leader within our industry with nearly three decades of
expertise as an accomplished public company CEO and senior
executive,” said Julie McHugh, chair of Ironwood’s Board. “We look
forward to leveraging Jay’s deep expertise as we seek to further
our mission to advance the treatment of GI diseases and redefine
the standard of care for GI patients.”
Mr. Shepard commented, “I am delighted to join the Ironwood
Board at such a dynamic time for the company and look forward to
being a part of its future as the company continues executing on
its GI-focused strategy.”
About Jay P. Shepard
Mr. Shepard was president and chief executive officer of
Aravive, Inc. (formerly Versartis, Inc.), a clinical-stage oncology
company, from May 2015 to January 2020, and served as a member of
its board of directors from December 2013 to April 2020, including
as chair of its board of directors from January 2020 to April 2020.
From 2012 until May 2015, Mr. Shepard was an executive partner at
Sofinnova Ventures, which he joined as an executive in residence in
2008. From 2010 to 2012, Mr. Shepard served as president and chief
executive officer and was a member of the board of directors of
NextWave Pharmaceuticals, Inc. (acquired by Pfizer Inc.). From 2005
to 2007, Mr. Shepard served as president and chief executive
officer and a member of the board of directors of Ilypsa, Inc.
(acquired by Amgen Inc.), and then as interim chief executive
officer of Relypsa, Inc. (Ilypsa’s spin-out company, which was
acquired by Galencia Group) until 2008 and as a member of the
Relypsa board of directors until 2010. Mr. Shepard currently serves
on the board of directors of Inovio Pharmaceuticals, Inc., Esperion
Therapeutics, Inc., and Craig Hospital and is chair of the board of
directors for the Christopher & Dana Reeve Foundation. Mr.
Shepard also served on the boards of directors of public companies,
Marinus Pharmaceuticals, Inc., Durect Corporation and InterMune,
Inc. (acquired by Roche Holding AG). Mr. Shepard holds a B.S. in
Business Administration from the University of Arizona.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI-focused
healthcare company dedicated to creating medicines that make a
difference for patients living with GI diseases. We discovered,
developed and are commercializing linaclotide, the U.S. branded
prescription market leader for adults with irritable bowel syndrome
with constipation (IBS-C) or chronic idiopathic constipation
(CIC).
Ironwood was founded in 1998 and is headquartered in Boston,
Mass. For more information, please visit our website at
www.ironwoodpharma.com or www.twitter.com/ironwoodpharma;
information that may be important to investors will be routinely
posted in both these locations.
SOURCE: Ironwood Pharmaceuticals, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201203005248/en/
Investors and Media: Meredith Kaya, 617-374-5082
mkaya@ironwoodpharma.com
Media: Beth Calitri, 978-417-2031
bcalitri@ironwoodpharma.com
Ironwood Pharmaceuticals (NASDAQ:IRWD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ironwood Pharmaceuticals (NASDAQ:IRWD)
Historical Stock Chart
From Jul 2023 to Jul 2024